iHuman
10 hedge funds and large institutions have $63.2M invested in iHuman in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
2.97% more ownership
Funds ownership: 0% → 2.97% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$20.6M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$15.6M |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$9.09M |
| 4 |
SCH
Sylebra Capital (HK)
Hong Kong
|
+$8.81M |
| 5 |
TAMH
Taikang Asset Management (HK)
Hong Kong
|
+$5.82M |
Top Sellers
IH Hedge Fund Activity: Q4 2020 in Review
10 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in iHuman (IH) for Q4 2020, worth a combined $63.2M.
Buyers outnumbered sellers: 10 funds opened new IH positions and 0 closed out — a net gain of 10 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $20.6M.
- 10 institutional investors held iHuman (IH) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $63.2M of iHuman stock for Q4 2020.
- 10 funds opened new iHuman positions in Q4 2020 and 0 closed out, a net change of +10 holders.
- The largest iHuman buyer in Q4 2020 was Morgan Stanley, an estimated $20.6M added.
Based on aggregated 13F filings for Q4 2020.